Insider transactions
Julie Rubinstein, serving as President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), completed a series of stock transactions between March 24 and March 26, 2026. Under a pre-arranged 10b5-1 trading plan, Rubinstein sold 57,180 shares of the company's common stock at prices ranging from $13.70 to $14.27, for aggregate proceeds of approximately $802,235.
In the same period, Rubinstein also exercised stock options to purchase 44,166 shares at an exercise price of $7.27 per share, for a total cost of $321,086. Following the sales and the option exercises, Rubinstein's direct holdings in Adaptive Biotechnologies stand at 468,892 shares.
Market context and valuation note
The company's stock is trading at $13.96, a level that represents a 69% appreciation over the last 12 months. Separately, an analysis referenced alongside these transactions indicates the company appears on a most-overvalued list based on a Fair Value assessment.
Recent financial performance and analyst reactions
Adaptive Biotechnologies reported fourth-quarter 2025 results that beat consensus expectations. The company posted earnings per share of -$0.09, compared with a forecasted -$0.18, a 50% positive surprise relative to the projection. Revenue for the quarter reached $71.7 million, ahead of the projected $59.33 million and representing a 20.85% upside to that estimate.
Following the quarterly results, several brokerages adjusted their views. BTIG raised its price target to $22.00 from $21.00 and maintained a Buy rating, citing robust growth in the company’s Minimal Residual Disease (MRD) segment. That MRD business expanded 54% year-over-year in the fourth quarter and grew 46% for the full year. TD Cowen also increased its price target to $21.00 in the wake of the earnings release. Piper Sandler reiterated an Overweight rating and highlighted expectations for substantial clonoSEQ volume growth.
Investor resources and coverage
For investors seeking additional research on valuation and growth prospects, the company is included among a broad set of covered U.S. equities in comprehensive Pro Research reports available through subscription research services.
These developments - the insider transactions, the option exercise, the recent earnings beat, and subsequent analyst updates - together paint a snapshot of active internal ownership moves and evolving external sentiment around Adaptive Biotechnologies.